The Human Cell Atlas launched in 2017 without a single plan to study children. Deanne Taylor, director of bioinformatics at the Children's Hospital of Philadelphia, caught that omission at a University of Pennsylvania presentation and immediately acted. She joined the Atlas's volunteer team, co-wrote its pediatric section, and published a 2019 paper making the scientific case for including children. The core problem: children's cells express genes differently than adults, and those differences can turn a tolerable adult drug into a fatal pediatric one, including chemotherapy agents that attack developing hearts.
In 2021, that advocacy produced results. The NIH awarded $38.5 million to the Developmental Genotype-Tissue Expression Project, or dGTEx, the first comprehensive database of healthy pediatric tissue. The project collects samples from deceased children whose families consented to donation, then maps gene expression across all major organ systems. Taylor's team handles data curation and standardization. The goal is a molecular baseline for the body's roughly 20,000 genes in healthy children, something that has never existed. She also leads the Kids First Data Resource Center and is pursuing funding to build 3D pediatric cell maps for HubMAP, a complementary effort to the Atlas.
The article is worth reading in full for two reasons. First, it traces how a single researcher forced a $38.5 million federal priority into existence through coalition-building, not politics. Second, it explains why the genome map completed in 2003 was never enough: knowing which genes exist tells you nothing about where and when they activate. Taylor and her collaborators are building that missing instruction manual, specifically for the bodies that medical research has treated as an afterthought.
[READ ORIGINAL →]